Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction
Indian Journal of Pharmacology · 2026-05 · 58 (3) · 280-282
DOI: 10.4103/ijp.ijp_818_25 ↗Kurz gefasst
Fallbericht in der Zeitschrift Indian Journal of Pharmacology, online erschienen am 01.05.2026. Verfasst von P Akshay Sankar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, AIIMS, Raipur, Chhattisgarh, India. Hauptthemen laut MEDLINE: Nivolumab, Folliculitis, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nivolumab, a human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by impairing T-cell suppression via the PD-1 pathway. Nivolumab is generally well-tolerated, with fewer treatment-related adverse events (AEs) than other systemic therapies. Here we report a case of nivolumab-induced folliculitis involving the lower limbs in a 35-year-old male. The patient had multiple follicular-based pustules over the bilateral legs with surrounding erythema. The patient was treated with topical steroids, which resulted in complete resolution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, AIIMS, Raipur, Chhattisgarh, India.
Zitieren
APA
Sankar, P. A., & Prabha, N. (2026). Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction. Indian Journal of Pharmacology, 58(3), 280-282. https://doi.org/10.4103/ijp.ijp_818_25
Vancouver
Sankar PA, Prabha N. Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction. Indian Journal of Pharmacology. 2026;58(3):280-282. doi:10.4103/ijp.ijp_818_25
BibTeX
@article{Sankar2026,
author = {Sankar, P Akshay and Prabha, Neel},
title = {Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction},
journal = {Indian Journal of Pharmacology},
year = {2026},
volume = {58},
number = {3},
pages = {280--282},
doi = {10.4103/ijp.ijp_818_25}
}
EUVIMED